Skip to main content
GoodMoatv1.3
Sign in
RXRX logo

RXRX

CompareEarnings: Aug 31, 2026

Recursion Pharmaceuticals Inc - Class A

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Recursion Pharmaceuticals Inc - Class A

Current Price

$2.93

-3.62%

GoodMoat Value

$0.63

78.5% overvalued
Profile
Valuation (TTM)
Market Cap$1.55B
P/E-2.76
EV—
P/B1.37
Shares Out527.40M
P/Sales23.27
Revenue$66.41M
EV/EBITDA—

Recursion Pharmaceuticals Inc - Class A (RXRX) Valuation

RXRX Fair Value Estimate

$0.6378.5% overvalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

RXRX Valuation Metrics

FCF$-378.28M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%

RXRX Valuation & Fair Value Analysis

Recursion Pharmaceuticals Inc - Class A (RXRX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Recursion Pharmaceuticals Inc - Class A is $0.63. The current stock price is $2.93, suggesting the stock is 364.2% overvalued.

The price-to-earnings (P/E) ratio is -2.76. Price-to-book ratio is 1.37. Price-to-sales ratio is 23.27. PEG ratio is 0.05.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Recursion Pharmaceuticals Inc - Class A's intrinsic value.